Evidence map›Paper›PMID 40821802›Full record

ReviewFrontiers in immunology2025

Adoptive cell therapy for cancer: combination strategies and biomarkers.

Shiyu Liu, Weibo Jiang, Jiyao Sheng, Lixuan Wang, Mengying Cui

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. T cell adaptation in chronic infections and tumors.Cellular & molecular immunology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shiyu LiuDepartment of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.
Weibo JiangOrthopedic Medical Center, The Second Hospital of Jilin University, Changchun, Jilin, China.
Jiyao ShengDepartment of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.
Lixuan WangDepartment of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.
Mengying CuiDepartment of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adoptive cell therapy (ACT) is a therapeutic approach that involves the isolation, modification, and expansion of immune cells

Indexed as

Biomarkers, TumorImmunotherapy, AdoptiveNeoplasmsAnimalsCombined Modality TherapyHumansLymphocytes, Tumor-InfiltratingReceptors, Chimeric AntigenTumor MicroenvironmentBiomarkers, TumorReceptors, Chimeric Antigenadoptive cell therapybiomarkersCAR-T cellscombination therapyimmunotherapyTCR-T cellsTILs

Identifiers

PMID40821802
PMCPMC12354659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.